Michigan public health officials on Monday reported 8,496 new cases of COVID-19 and 46 additional virus deaths in the past three days.

The three-day total of cases brought the total number of confirmed cases and deaths in the state to 1,090,021 and 21,609 deaths since the start of the pandemic.

According to the Michigan Department of Health and Human Services (MDHHS), these totals represent test data collected Thursday and Friday. The MDHHS publishes new case, death and vaccination numbers every Monday, Wednesday and Friday with new outbreak data released every Monday.

Of the 46 reported deaths, 15 were identified during a review of vital records. Over the past three days, the state has recorded an average of 2,832 cases per day per 100,000 population, compared to 4,149 cases per day per 100,000 population from October 14 to 15, a drop of 31%.

The state’s average 7-day COVID-19 case and positivity rates remain high due to the spread of the Delta variant among unvaccinated residents, including children.

Michigan’s 7-day average case rate is 241 cases per day per 100,000 population, down from the previous 7 days at 301. The state remains in the high community transmission category, which is defined by the CDC as an average of at least 100 new cases per day per 100,000 population over a 7-day period.

The state’s average 7-day test positivity rate continues to average 8-10%. The CDC also reports that 77% of all U.S. counties have high levels of community transmission, which is a 10% drop from a week ago. Michigan’s 83 counties remain in strong transmission.

Over the past 7 days, Oakland County has recorded an average of 212 cases per day per 100,000 population, down 4% from the previous 7 days, according to the CDC. Wayne County’s 7-day average case rate is 203 cases per day per 100,000 population, an 11% increase from the previous 7 days, while Macomb County’s 7-day case rate has increased by 9% over the previous 7 days to reach 281 cases per day per 100,000 population. residents.

Hospitalizations

Statewide, more than 2,000 Michiganders are hospitalized with confirmed positive COVID-19, the majority being in southeast Michigan, with more than 80% of the state’s hospital beds occupied.

Last week, the MDHHS reported that the percentage of inpatient hospital beds occupied by people with COVID-19 was 9.3%, up from 8% the week before. This percentage has been increasing for 12 weeks.

The MDHHS also reported that the volume of COVID-19 patients in intensive care increased by 15% from the previous week, while the number of emergency room visits increased by 4.9% from the previous week, with new hospital admissions increasing last week for most age groups. . The largest week-over-week increases in the rate of new admissions occurred among the 12 to 17 and 60 to 69 age groups, with increases totaling 85% and 47%, respectively.

The 7-day average of new cases per day in children aged 10 to 19 is 596. This is by far the highest case rate of any age group.

Michigan hospitals average about 34 pediatric admissions under the age of 18 per day, with more than 50% of children hospitalized with COVID-19 having no reported underlying conditions. Every day, more than 425 children under the age of 12 are infected with COVID-19, 50 more children a day than last week.

The 7-day average pediatric case rate, which includes children 12 and under, rose to 305.6 cases per day last week, from 269.4 cases per day the week before.

Oakland County hospitals saw a 17% decrease in the number of new COVID-19 admissions, 198 patients, from the previous 7 days, according to the CDC. Wayne County hospitals saw a 6% decrease in the number of new COVID-19 admissions from the previous 7 days, totaling 214 patients, while Macomb County hospitals saw a 29% decrease in the number of new COVID-19 admissions compared to the previous one. 7 days with 60 patients.

Immunization coverage

The state’s immunization coverage rate for residents 16 and older is 68.4%, with more than 5.5 million residents receiving at least one dose. The vaccination coverage rate for residents aged 12 and over is 63.3%.

Vaccination coverage rates included 41.3% for 12-15 year olds, 48.7% for 16-19 year olds, 46.8% for 20-29 year olds and 57% for 30-39 year olds.

Among older groups, vaccination rates are 60.6% for 40-49 year olds, 71.1% for 50-64 year olds, 85.1% for residents aged 65-74 and 81, 6% for Michiganders aged 75 and over.

More than 350,000 booster and third dose doses have been administered statewide, the majority of which are given to Michiganders aged 50 and over.

Revolutionary cases

Between January 1 and October 5, the MDHHS reported 38,571 breakthrough cases, which is less than 1% of those fully vaccinated. These are people confirmed to have COVID-19 at least 14 days after being fully vaccinated.

Of these breakthrough cases, 1,412 cases were hospitalized and 574 people died (504 were aged 65 and over).

New data from the MDHHS shows that between January 15 and October 5, 93.7% of all new cases statewide were in people not fully vaccinated (488,965 of 521,677). Of the 14,924 Michiganders hospitalized with COVID-19 during this period, 13,512 or 90.5% were not fully vaccinated.

In addition, 90.8% of all deaths from COVID-19 during this period (5,662 of 6,236) were in people not fully immunized.

Between September 6 and October 4, all new cases, hospitalizations and deaths reported statewide accounted for 16%, 24% and 28% of Michigan’s fully vaccinated population.

Schools

On Monday, the MDHHS reported 101 new K-12 school outbreaks and clusters involving 858 cases.

The MDHHS recently revised its definition of a school-associated epidemic and a school-associated cluster to promote consistent reporting across states. A school-associated epidemic is based on an exposure link between cases where there is a confirmed epidemiological link in the school setting or an extracurricular activity sanctioned by the school. A school-associated cluster represents cases where a definitive exposure link has not been established, but there is probably no known epidemiological link to a case outside of school.

Going forward, the MDHHS will report clusters and outbreaks as combined totals every Monday. For example, the MDHHS reported on Monday an outbreak and cluster at Eisenhower High School in Macomb County involving 53 cases among students and staff.

Currently, 60% of Michigan public school students in more than 200 school districts are required to wear face masks indoors under 10 local health department orders including: Kalamazoo, Kent, Ottawa (K-6 ); Benzie-Leelanau, Northwestern Department of Health, Oakland and Wayne (K-12); and Genesee, Ingham and Washtenaw (preK-12).

The MDHHS continues to report that school districts with fewer mask rules have seen higher case rates and faster increases in cases than districts with mask rules in place. The largest increase in cases during and after the start of the school year concerns 5-18 year olds.

As of October 1, an informal survey of local health departments identified 104 schools where learning time has been directly affected by COVID-19, including closed schools, closed classrooms and student quarantines.

Booster / third dose

Last week, the Food and Drug Administration (FDA) advisory committee voted in favor of recommending second and third doses for vaccinees Johnson & Johnson and Moderna COVID-19.

The second dose of J&J is recommended at least two months after the first dose and the third dose of Moderna, which will be a half dose, is recommended at least six months after the second dose. This is only a recommendation, with the FDA and CDC required to approve additional doses before they can be administered to eligible groups.

The National Institutes of Health recently published a study that adds weight to the idea of ​​mixing vaccines. The study indicates that people who were vaccinated with the J&J vaccine might be better protected if they were boosted with the mRNA doses from Moderna or Pfizer. But there are also questions about this study.

The results included people who received the Johnson & Johnson vaccine and a Moderna booster produced a 76-fold increase in antibodies in 15 days; People who received the Johnson & Johnson vaccine and a Pfizer booster saw their antibodies increase 35-fold in 15 days; and people who got a second injection of Johnson & Johnson also benefited, but only got a fourfold increase in antibodies.

Drugmaker Merck has asked U.S. regulators to clear its home pill for the treatment of mild to moderate symptoms of COVID-19, which would add an entirely new and easy-to-use weapon to the global arsenal against the pandemic.

If cleared by the Food and Drug Administration – a decision that could come in a few weeks – it would be the first pill shown to treat the disease. All other FDA-backed COVID-19 treatments require an intravenous or injection.

Last week, Pfizer submitted research to the FDA on the effectiveness of its COVID-19 vaccine in children aged 5 to 11. The FDA’s Vaccines and Related Biologics Advisory Committee will meet on October 26 to consider granting this emergency use authorization.

Later this year, the drugmaker and its partner, Germany’s BioNTech, plan to submit initial vaccine data for children aged 6 months to four years to the FDA to consider clearance for emergency use.

Currently, third doses of the Pfizer COVID-19 vaccine are available to all Americans 65 and older, people 18 and older living in long-term care facilities, people 18 to 64 years at high risk of severe COVID-19 with underlying medical conditions and people aged 18 to 64 whose jobs put them at increased risk of exposure and transmission of the virus, including healthcare workers , first responders, education staff, food and agricultural workers, manufacturing workers, correctional workers, postal workers, transit workers, and grocery store workers.

All people in these groups must be at least six months away from their second dose of Pfizer to receive the third injection. The list of eligible recipients for the third dose may be updated in the future.

In August, Booster Doses Pfizer and Moderna were granted emergency use authorization for immunocompromised Americans such as patients with organ transplants, active cancer and HIV at least four weeks into their series. two doses, as well as people 65 years of age and over or those at high risk of serious illness.

-The Associated Press contributed to this report


Source link

Leave a Reply

Your email address will not be published.